Jazz Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Jazz Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 16.3% ve 5.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.3%

Kazanç büyüme oranı

15.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	5.6%
Gelecekteki özkaynak getirisi	15.2%
Analist kapsamı	Good
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:JAZZ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,490	645	1,586	1,431	16
12/31/2025	4,315	593	1,393	1,501	19
12/31/2024	4,039	515	1,057	1,350	19
9/30/2024	3,993	463	1,102	1,165	N/A
6/30/2024	3,910	395	1,017	1,073	N/A
3/31/2024	3,843	331	983	1,039	N/A
12/31/2023	3,834	415	1,049	1,092	N/A
9/30/2023	3,794	80	867	1,267	N/A
6/30/2023	3,763	-87	987	1,377	N/A
3/31/2023	3,738	-156	918	1,384	N/A
12/31/2022	3,659	-224	774	1,272	N/A
9/30/2022	3,584	-19	984	1,108	N/A
6/30/2022	3,481	-52	809	964	N/A
3/31/2022	3,300	-450	622	702	N/A
12/31/2021	3,094	-330	733	779	N/A
9/30/2021	2,863	-161	711	787	N/A
6/30/2021	2,626	40	708	771	N/A
3/31/2021	2,436	518	750	912	N/A
12/31/2020	2,364	239	520	900	N/A
9/30/2020	2,280	179	455	801	N/A
6/30/2020	2,217	133	478	881	N/A
3/31/2020	2,188	280	509	847	N/A
12/31/2019	2,162	523	594	776	N/A
9/30/2019	2,056	609	726	907	N/A
6/30/2019	1,988	656	676	791	N/A
3/31/2019	1,954	486	646	834	N/A
12/31/2018	1,891	447	667	799	N/A
9/30/2018	1,851	520	642	785	N/A
6/30/2018	1,793	434	N/A	753	N/A
3/31/2018	1,687	447	N/A	696	N/A
12/31/2017	1,619	488	N/A	693	N/A
9/30/2017	1,579	372	N/A	669	N/A
6/30/2017	1,541	399	N/A	613	N/A
3/31/2017	1,528	408	N/A	605	N/A
12/31/2016	1,488	397	N/A	592	N/A
9/30/2016	1,432	363	N/A	531	N/A
6/30/2016	1,399	361	N/A	573	N/A
3/31/2016	1,352	335	N/A	587	N/A
12/31/2015	1,325	330	N/A	532	N/A
9/30/2015	1,312	328	N/A	545	N/A
6/30/2015	1,278	266	N/A	499	N/A
3/31/2015	1,235	222	N/A	434	N/A
12/31/2014	1,173	58	N/A	408	N/A
9/30/2014	1,081	32	N/A	353	N/A
6/30/2014	1,006	82	N/A	354	N/A
3/31/2014	923	80	N/A	287	N/A
12/31/2013	872	216	N/A	288	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: JAZZ 'nin tahmini kazanç büyümesi (yıllık 16.3% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: JAZZ şirketinin kazançlarının (yıllık 16.3% ) US pazarından (yıllık 15.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: JAZZ şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: JAZZ şirketinin gelirinin (yıllık 5.6% ) US pazarından (yıllık 9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: JAZZ şirketinin gelirinin (yıllık 5.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: JAZZ 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.2 %).

Jazz Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 25%

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 41%

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Recent updates

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Executive VP & Chief Legal Officer recently sold US$457k worth of stock

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Consensus EPS estimates increase by 11%

Executive VP & Chief Legal Officer notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024

Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Consensus EPS estimates increase by 25%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

New minor risk - Insider selling

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab

Executive VP & Chief Legal Officer recently sold US$548k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Executive VP & CFO recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 41%

New minor risk - Earnings quality

Full year 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Updated View On Jazz Pharmaceuticals' 2025 Goals

Insufficient new directors

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Third quarter 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation